(2S)-2-[2-(tert-butylamino)-2-oxoethyl]-3,3-dimethylbutanoic acid | 192202-54-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (2S)-2-[2-(tert-butylamino)-2-oxoethyl]-3,3-dimethylbutanoic acid
• CAS: 192202-54-3
• 化学式: C₁₂H₂₃NO₃
• 分子量: 229.32
• InChiKey: WYLKIJGDKQMQHC-MRVPVSSYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  66.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (2S)-2-[2-(tert-butylamino)-2-oxoethyl]-3,3-dimethylbutanoic acid 在 N-甲基吗啉 、 盐酸 、 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成
  参考文献：
  名称：

  含有新型（羟乙基）酰胺等排物的有效HIV蛋白酶抑制剂。

  摘要：

  已经合成了一系列含有新的（羟乙基）酰胺基琥珀酰基核心的HIV蛋白酶抑制剂。这些拟肽结构在低纳摩尔浓度下抑制病毒蛋白酶活性（HIV-1蛋白酶的IC50 <10 nM）。测定出的针对抑制剂19的抑制常数（Ki）分别为针对HIV-1的7.5pM和针对HIV-2蛋白酶的1.2nM。在细胞培养测定中，几种化合物（19-24）抑制HIV-1复制，有效浓度为50％（EC50）= 3.7-35 nM。发现该系列抑制剂在口服给药后在大鼠中表现出较差的生物利用度（<10％）。讨论了这些化合物的合成和生物学性质。此外，

  DOI：

  10.1021/jm9606608
• 作为产物：
  描述：

  2-tert-butyl-butanedioic acid diethyl ester 在 吡啶 、 盐酸 、 乙酸酐 作用下， 反应 5.0h， 生成 (2S)-2-[2-(tert-butylamino)-2-oxoethyl]-3,3-dimethylbutanoic acid
  参考文献：
  名称：

  含有新型（羟乙基）酰胺等排物的有效HIV蛋白酶抑制剂。

  摘要：

  已经合成了一系列含有新的（羟乙基）酰胺基琥珀酰基核心的HIV蛋白酶抑制剂。这些拟肽结构在低纳摩尔浓度下抑制病毒蛋白酶活性（HIV-1蛋白酶的IC50 <10 nM）。测定出的针对抑制剂19的抑制常数（Ki）分别为针对HIV-1的7.5pM和针对HIV-2蛋白酶的1.2nM。在细胞培养测定中，几种化合物（19-24）抑制HIV-1复制，有效浓度为50％（EC50）= 3.7-35 nM。发现该系列抑制剂在口服给药后在大鼠中表现出较差的生物利用度（<10％）。讨论了这些化合物的合成和生物学性质。此外，

  DOI：

  10.1021/jm9606608

文献信息

• Hepatitis C inhibitor peptide analogs
  申请人：Bailey D. Murray

  公开号：US20060019905A1

  公开（公告）日：2006-01-26

  Compounds of formula (I): wherein R 1 , R 2 , R 3 , R 4 , R 5 , Y, n and m are as defined herein. The compounds are useful as inhibitors of HCV NS3 protease.

  式（I）的化合物：其中R1、R2、R3、R4、R5、Y、n和m的定义如本文所述。这些化合物可用作HCV NS3蛋白酶的抑制剂。
• Peptide backbone replacement of hepatitis C virus NS3 serine protease C-terminal cleavage product analogs: Discovery of potent succinamide inhibitors
  作者：Murray D. Bailey、Josée Bordeleau、Michel Garneau、Mélissa Leblanc、Christopher T. Lemke、Jeff O’Meara、Peter W. White、Montse Llinàs-Brunet

  DOI：10.1016/j.bmcl.2013.05.045

  日期：2013.8

  A number of potent peptidic inhibitors of the NS3 protease have been described in the literature based on a substrate-based approach. In an on-going effort to reduce the peptidic character of this class of inhibitors, two novel series of analogs have been prepared in which the usual P3 amino acid residue is replaced by a succinamide fragment. This new backbone modification not only reduces the peptidic nature of traditional inhibitors but also provides new SAR opportunities for the capping group. Optimization of each of these two series resulted in inhibitors with sub-nanomolar potencies. (C) 2013 Elsevier Ltd. All rights reserved.
• PROCESS FOR THE PREPARATION OF alpha-ACYLOXY beta-FORMAMIDO AMIDES
  申请人：Ruijter Eelco

  公开号：US20120330015A1

  公开（公告）日：2012-12-27

  The present invention relates to a process for the preparation of a compound of the general Formula (I), comprising: a) reacting a compound of the general Formula (II) with a compound of the Formula III R 2 COOH and a compound of the general Formula IV R 3 NC under such conditions that compound I is formed, wherein R 1 represents a substituted or unsubstituted alkyl, alkenyl, alkynyl, aromatic or non-aromatic, mono-, di- or tricyclic, or heterocyclic structure, and R 2 represents a substituted or unsubstituted alkyl, alkenyl, alkynyl, aromatic or non-aromatic, mono-, di- or tricyclic, or heterocyclic structure, and R 3 represents a substituted or unsubstituted alkyl, alkenyl, or alkynyl structure. In further aspect the subject invention relates to the use of the obtained products as intermediates for various peptidomimetics, and preferably as a building block in a convergent synthesis of prolyl dipeptide structures.
• PROCESS FOR THE PREPARATION OF ALPHA-ACYLOXY BETA-FORMAMIDO AMIDES
  申请人：RUIJTER Eelco

  公开号：US20140213788A1

  公开（公告）日：2014-07-31

  The present invention relates to a process for the preparation of a compound of the general Formula (I), comprising: a) reacting a compound of the general Formula (II) with a compound of the Formula III R 2 COOH and a compound of the general Formula IV R 3 NC under such conditions that compound I is formed, wherein R 1 represents a substituted or unsubstituted alkyl, alkenyl, alkynyl, aromatic or non-aromatic, mono-, di- or tricyclic, or heterocyclic structure, and R 2 represents a substituted or unsubstituted alkyl, alkenyl, alkynyl, aromatic or non-aromatic, mono-, di- or tricyclic, or heterocyclic structure, and R 3 represents a substituted or unsubstituted alkyl, alkenyl, or alkynyl structure. In further aspect the subject invention relates to the use of the the obtained products as intermediates for various peptidomimetics, and preferably as a building block in a convergent synthesis of prolyl dipeptide structures.
• US7696242B2
  申请人：——

  公开号：US7696242B2

  公开（公告）日：2010-04-13